MedTrace Logo

Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

NCT07422558 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2026-02-20

No results posted yet for this study

Summary

Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.

Conditions

  • Procedural Pain

Interventions

DRUG

Nalbuphine

Intravenous nalbuphine 0.1mg/kg administred 60second prior to induction with propofol

DRUG

Lidocaine

Intravenous lidocaine 4.5mg/kg (maximum 300mg) administred 60sec prior to induction with propofol

Sponsors & Collaborators

  • Hayatabad Medical Complex

    lead OTHER_GOV

Principal Investigators

  • Dr.Arina kore Trainee medical officer, MBBS · PGMI/Hayatabad Medical complex(HMC),Peshawar

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-08-01
Completion
2026-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07422558 on ClinicalTrials.gov